Rapid sepsis test

HIVCandida aurisfor PCR

World’s first fully automated PCR test for detection of the multidrug-resistant fungus at the point of care Vivalytic test detects Candida auris in under an hour at the point of care, making it the world’s first test suitable for screenings. Candida auris infection rates are on the rise in Germany and can cause severe infections, for example of the bloodstream (sepsis). Hospitals can use the new screening test to detect colonization, allowing them to implement measures to contain outbreaks. Waiblingen – Bosch Healthcare Solutions has developed a PCR test for detecting Candida auris (C. auris) on the Vivalytic platform. The test is a global innovation now available for order from distribution partners including Randox Laboratories Ltd. and R-Biopharm. This test enables the fully automated detection of the frequently multi-resistant fungus in less than an hour at the point of care. The rapid testing capability also makes it suitable for carrying out screenings when necessary. In contrast, traditional culture tests in centralized laboratories require one to three days1, delaying diagnosis and the initiation of targeted treatment. “Considering the heightened risk of severe progression in individuals with pre-existing conditions, we have developed a new test that enables clinics to respond more swiftly,” states Marc Meier, managing director of Bosch Healthcare Solutions. Patients with compromised immune systems, such as those in intensive care, individuals with serious underlying conditions such as diabetes, or those who are immunosuppressed due to cancer or HIV, as well as patients about to undergo invasive surgery,